---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-181093"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:40:13.351699+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Guardant Health appoints Dr. Manuel Hidalgo Medina to board effective July 17

## Summary
- Board increased to nine seats; Dr. Hidalgo appointed as Class II director, term expiring at 2026 annual meeting.
- Dr. Hidalgo is Chief of Hematology/Medical Oncology at Weill Cornell Medicine and also serves on Bristol-Myers Squibb's board.
- Received standard non-employee director compensation: stock option and RSU awards each valued at $362,500, vesting over four years.
- Appointed to the nominating and corporate governance committee of the board.

## SEC filing metadata
- accession: 0001193125-24-181093
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000119312524181093/0001193125-24-181093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000119312524181093/d771601d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-181093
- JSON: https://secwatch.observer/filing/0001193125-24-181093.json
- Plain text: https://secwatch.observer/filing/0001193125-24-181093.txt

## Key facts
- Executive change
  Manuel Hidalgo Medina was appointed as Class II Director at Guardant Health, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312524181093/0001193125-24-181093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.